DGS - COVID-19: Rastreio de Contactos

DGS - COVID-19: Rastreio de Contactos

Norma da Direção-Geral da SaúdeDe acordo com a Organização Mundial de Saúde (OMS), a Comissão Europeia e o Centro Europeu para a Prevenção e Controlo de Doenças (ECDC) um efetivo rastreio de contactos (identificação, avaliação do risco e...
AMP - Population-based Estimates for High Risk of Severe COVID-19 Disease due to Age and Underlying Health Conditions

AMP - Population-based Estimates for High Risk of Severe COVID-19 Disease due to Age and Underlying Health Conditions

Acta Médica PortuguesaCOVID-19 is a viral respiratory disease, which became a global threat to public health. Specific subsets of the population are more vulnerable, namely those with chronic diseases. We aimed to estimate the share of the...
AMP - Recursos Humanos de Medicina Intensiva em Portugal na Era Pós COVID

AMP - Recursos Humanos de Medicina Intensiva em Portugal na Era Pós COVID

Acta Médica PortuguesaCom a epidemia de poliomielite, no início da década de 50 do século XX, num contexto de recursos escassos surgiu a evidência de que era possível salvar doentes em falência orgânica desde que sujeitos a atitudes e gestos...
AMP - Estratégia de Saúde Pública para a Pandemia COVID-19 em Portugal: Contribuições da Experiência Internacional

AMP - Estratégia de Saúde Pública para a Pandemia COVID-19 em Portugal: Contribuições da Experiência Internacional

Acta Médica Portuguesa"Carta ao Editor - Foi com extremo agrado que li o artigo “Estratégia de Saúde Pública para a Pandemia COVID-19 em Portugal: Contribuições da Experiência Internacional”. Consistem em experiências de grande importância, que...
AMP - Os Constrangimentos Conduzem a Oportunidades para a Educação Médica em Tempos de Pandemia COVID-19

AMP - Os Constrangimentos Conduzem a Oportunidades para a Educação Médica em Tempos de Pandemia COVID-19

Acta Médica PortuguesaThe COVID-19 pandemic poses significant health constraints to us both as individuals and as a community. Medical schools deal with that at a student, faculty and society level. Both students and faculty are dealing with...
JAMA - Opting Out of Vaccines for Your Child

JAMA - Opting Out of Vaccines for Your Child

JAMA Network

During the ongoing coronavirus disease 2019 (COVID-19) pandemic, there has been a critical decline in children receiving their routine vaccines.

The Lancet - Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study

The Lancet - Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study

The risk of vertical and perinatal transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, which causes COVID-19), the most appropriate management, and the neonate's risk of developing COVID-19 during the perinatal period are...
NEJM - Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

NEJM - Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

The New England Journal of MedicineHydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.
ECDC - COVID Worldwide Sources

ECDC - COVID Worldwide Sources

European Centre for Disease Prevention and Control

COVID Worldwide Sources

APEP - SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

APEP - SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

APEP

Memory T cells induced by previous pathogens can shape the suspectibillity to, and clinical severity of, subsequent infections.

NEJM - Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

NEJM - Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

The New England Journal of MedicineA recent article suggested the rapid decay of anti–SARS-CoV-2 IgG in early infection,1 but the rate was not described in detail. We evaluated persons who had recovered from Covid-19 and referred themselves...
JAMA - Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

JAMA - Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

JAMA NETWORKPatients with coronavirus disease 2019 (COVID-19) are at increased risk of thrombosis. However, studies have been limited in size, did not report all thrombotic events, and focused on patients with severe disease hospitalized in...
The Lancet -  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

The Lancet - Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

The LancetThe pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike...
AMP - Porque Deve o Financiamento para a Recuperação Pós-Pandemia SARS-CoV-2 Ser Usado para Criar um Programa de Médicos-Cientistas?

AMP - Porque Deve o Financiamento para a Recuperação Pós-Pandemia SARS-CoV-2 Ser Usado para Criar um Programa de Médicos-Cientistas?

Acta Médica PortuguesaIn Portugal, as in many other countries worldwide, medical doctors are rarely allowed to have protected research time. As a result, almost all research conducted by physicians is done afterhours, thus potentially...
LANCET - Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

LANCET - Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

The LancetThis is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate...
Primeiro89101113151617Último
Categorias

Categorias

Arquivo de Notícias

Arquivo